524696-16-0Relevant articles and documents
Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure
Watanabe, Mizuki,Kazuta, Yuji,Hayashi, Hideki,Yamada, Shizuo,Matsuda, Akira,Shuto, Satoshi
, p. 5587 - 5596 (2006)
The stereochemical diversity-oriented conformational restriction strategy can be an efficient method for developing specific ligands for drug target proteins, especially in cases where neither the bioactive conformation nor the pharmacophore is known. To
Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure
Kazuta, Yuji,Hirano, Kazufumi,Natsume, Kentaro,Yamada, Shizuo,Kimura, Ryohei,Matsumoto, Shun-Ichiro,Furuichi, Kiyoshi,Matsuda, Akira,Shuto, Satoshi
, p. 1980 - 1988 (2007/10/03)
A series of cyclopropane-based conformationally restricted analogues of histamine, the "folded" cis-analogues, i.e., (1S,2R)-2-(aminomethyl)-1-(1H-imidazol-4-yl)cyclopropane (11), (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane (13), and their e
